#United States #Houston #PACE #CAR-T #AAVivo

AAVivo, Inc. to Present at BIOHK2025

AAVivo, Inc., a pioneering company in the biotechnology sector, is set to unveil its innovative Precision AAV Capsid Engineering (PACE) platform at the upcoming BIOHK2025 conference. This event, scheduled for September 10, 2025, in Hong Kong, serves as a significant platform for discussing advancements in biotechnology and biotherapeutics. The presentation will be led by Dr. Haifeng Chen, the Chief Technology Officer and Founder of AAVivo.

What is the PACE Platform?

The PACE platform is designed to transform conventional adeno-associated virus (AAV) vectors into precision-targeted gene delivery systems. This revolutionary approach enhances the efficacy of CAR-T therapies by allowing for the in vivo generation of CAR-T cells, which can be specifically tailored to target various types of malignant cells. By optimizing AAV vectors to deliver therapeutic agents directly to specific cell types or tissues, AAVivo aims to create more effective and personalized treatments for cancer patients.

Key Features of PACE

• - Precision Targeting: The PACE platform utilizes advanced engineering techniques to ensure that AAV vectors can selectively deliver therapeutic payloads to desired tissues. This targeted approach not only improves treatment effectiveness but also minimizes potential side effects associated with traditional therapies.
• - Versatile Applications: The therapies developed using the PACE platform can serve multiple purposes, from enhancing immune cell function to redirecting cells for localized therapy delivery or directly eliminating cancer cells.
• - Part of a Larger Initiative: PACE is a fundamental component of AAVivo's IntelligentAAV (iAAV) platform, which aims to expedite the development of novel precision biotherapies that the body can produce, thereby offering long-term disease control.

AAVivo's Broader Vision

Beyond the PACE platform, AAVivo is committed to revolutionizing the field of gene therapy through its proprietary technologies. The company's suite of innovations includes:

• - BAC-to-AAV Technology: This technique enables large-scale, cost-effective manufacturing of AAV, ensuring that therapies can be produced efficiently to meet clinical demands.
• - Selective Toxin Packaging (SToP): A safety feature designed to shield the delivery of potent therapeutic genes with microRNA, thereby enhancing patient safety.
• - High Yield and Scalability: AAVivo's technologies promise higher yields and enhanced potency of therapies without requiring lymphodepletion, which is essential for improving patient outcomes.

Current Development Pipeline

AAVivo is not resting on its laurels. Its current development pipeline features several promising products targeting various types of cancer. Notably:

• - AVO-100: Aimed at treating B-cell malignancies.
• - AVO-200 & AVO-300: Focusing on therapies for solid tumors.

This pipeline positions AAVivo as a frontrunner in the burgeoning gene therapy market, offering exceptional opportunities for investors interested in impactful biotechnological innovations.

Conclusion

The presentation at BIOHK2025 is expected to highlight the significant strides AAVivo has made in precision-targeted biotherapeutics and will underscore the potential of the PACE platform to redefine CAR-T therapies.

Event Details

• - Date: September 10, 2025
• - Time: 3:00 PM HKT

AAVivo is based in Houston, Texas, and continues to push the boundaries of what is possible in the field of gene therapy. For further details, you can visit their official website at AAVivo.